Pietras and colleagues36 were the first to demonstrate that combined receptor blockade using an anti-HER2 antibody and tamoxifen resulted in greater combined efficacy compared to either the anti-HER2 antibody or anti-estrogen–alone controls against HER2-overexpressing human breast cancer cells co-expressing ER. This evidence concerns the gene ERBB2 and breast carcinoma.